Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?

Myriad Genetics reported Q3 adjusted break-even EPS versus a Zacks estimate loss of $0.01, with GAAP net loss of $0.29 and total revenue of $205.7 million, down 3.6% year-over-year and 0.24% ahead of the consensus. For 2025 the company guided revenue of $818–828 million (consensus $821.9M) and adjusted EPS between -$0.02 and $0.02 (consensus $0.01); consensus estimates have since moved down ~7.9%, the stock is up ~8.7% since the quarter, and Zacks assigns a Rank #3 and VGM Score A.

Analysis

Market structure: Myriad (MYGN) benefits from a beat vs. consensus and a strong Growth/Momentum profile, but the underlying business shows revenue -3.6% y/y and guidance that implies flat organic growth ($818–828M) — a setup where positive sentiment can drive short-term outperformance (we saw +8.7% since earnings) while fundamentals limit durable re-rating. Competitors and payers are pressured: larger integrated labs win when testing volume softens, and any negative reimbursement change would immediately transfer share to lower-cost providers. Cross-asset: expect elevated equity volatility and options IV in diagnostics; limited direct impact on FX/commodities, but modest credit spread sensitivity for highly levered healthcare names if sector risk-off accelerates.

Risk assessment: Tail risks include an adverse Medicare/payer coverage decision or a major client contract loss — each could trigger >20% downside in 3–6 months given slim adjusted EPS guidance (-$0.02 to $0.02). Near-term (days-weeks) risks are earnings/estimate revisions and IV spikes; medium-term (3–12 months) hinge on new product adoption and payer rulings; long-term (12–36 months) depends on successful diversification into oncology panels and M&A integration. Hidden dependencies: revenue concentration by test line, lab utilization rates, and data-privacy/regulatory rulings that can abruptly change payer behavior.

Trade implications: Direct tactical play is a modest long with protection: favor a 2–3% net-long position in MYGN or a defined-risk call spread to capture re-rating if management secures new payer contracts within 3–6 months; avoid naked long exposure given estimate revisions (-7.9%). Pair trade: long MYGN / short a broader large-cap biotech (e.g., BIIB) at 0.6 hedge ratio to isolate diagnostics-specific upside while hedging beta; expect mean reversion within 1–3 months. Options: buy a 6–9 month MYGN call spread (caps cost, captures 20–40% upside) and sell short-dated calls to finance if IV rises around catalyst windows.

Contrarian angles: Consensus overlooks binary payer catalysts — the street trimmed estimates yet rewarded the stock; that divergence implies upside only on concrete contract/favorable Medicare news, so current rally is likely overdone absent catalysts. Conversely, long-term upside is underpriced if Myriad converts oncology companion diagnostics and stabilizes revenue growth; historical parallels (diagnostics reratings after payer wins) show 40–80% moves but only after documented coverage wins. Unintended consequence: activists or acquirers may surface if valuation stalls, compressing volatility but capping upside.

Key Decisions for Investors

• Establish a 2–3% long position in MYGN now, paired with a protective 12% trailing stop; hold 3–6 months and trim/exit if FY25 revenue midpoint is missed by >2% or adjusted EPS guidance moves below -$0.05.
• Implement a defined-risk options trade: buy MYGN Jan 2026 call spread (approx. 6–9 month tenor) 10–25% OTM to cap cost and target 30–40% ROI on a positive payer/contract catalyst; close positions 10–14 days before FY26 earnings to avoid IV crush.
• Construct a relative-value pair: long MYGN vs. short BIIB sized at a 0.6 hedge ratio to neutralize market beta; target capture window 1–3 months and rebalance if pair diverges >8%.
• Reduce large-cap growth biotech exposure by 1–2% of portfolio and reallocate into selective diagnostics/precision medicine names (including MYGN) over next 30 days, conditional on monitoring Medicare/payer rulings expected in the next 30–60 days — if a negative coverage decision is announced, liquidate diagnostics increment until impact is quantified.